Mochida Pharmaceutical Co., Ltd. (MFY) Stock Price & Analysis
MFY Stock Chart & Stats
- Day’s Range
- EUR 18.30 - EUR 18.30
- 52-Week Range
- EUR 16.20 - EUR 21.80
- Previous Close
- EUR 18.10
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 632.99M
- Enterprise Value
- EUR 95.36B
- Total Cash (Recent Filing)
- EUR 28.41B
- Total Debt (Recent Filing)
- EUR 10.81B
- Price to Earnings (P/E)
- 12.6
- Beta
- 0.46
- Next Earnings
- Nov 09, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.46%
Bulls Say, Bears Say
Bulls Say
Revenue And Profit Rebound
The recovery in revenue and net income indicates renewed product demand and improved earnings capacity. If sustained, stronger operating performance can provide resources for research, commercialization and continued expansion in core therapeutic areas.
Conservative Balance Sheet
A conservative balance sheet gives Mochida financial flexibility to fund development, licensing and commercial activities without heavy dependence on borrowing. This resilience can help the company absorb product or market setbacks while preserving strategic options.
Focused Prescription Portfolio
Concentration in defined specialty areas can support focused medical expertise, targeted commercialization and stronger relationships with Japanese healthcare providers. Its established sales and distribution network also supports repeat access to hospitals, clinics and pharmacies.
Bears Say
Unreliable Cash Conversion
Repeated swings between positive and negative operating and free cash flow indicate that reported profits do not consistently translate into cash. Working-capital volatility could constrain reinvestment, shareholder returns and funding for pipeline activities.
Volatile Earnings Margins
The uneven margin trajectory suggests that improved profitability may not be fully structural. Variation in product mix, pricing, development costs or other operating factors could make future earnings less predictable than the recent rebound implies.
Recent Debt Increase
Although Mochida remains conservatively financed, the sharp increase in total debt is a developing balance-sheet risk. If borrowing continues while cash conversion remains volatile, interest obligations could reduce flexibility and weaken resilience during earnings pressure.
Mochida Pharmaceutical Co., Ltd. News
MFY FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Is Mochida Pharmaceutical Co., Ltd. overvalued?
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Mochida Pharmaceutical Co., Ltd.
Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuticals, diagnostic solutions, and skincare lines. The company's extensive pharmaceutical portfolio includes treatments for a variety of conditions, such as cardiovascular issues, pain (analgesics), gastrointestinal ailments, neurological disorders, infections (anti-infectives), diabetes (antidiabetics), and cancer (oncological agents). Additionally, it provides hormone and biological preparations, alongside biosimilars, catering to therapeutic areas like dermatology, psychiatry, obstetrics, and gynecology. In diagnostics, Mochida produces various reagents, particularly those utilized for fertility and infertility assessments. Its skincare division features products designed for facial, body, and hair care. Beyond its existing product range, Mochida Pharmaceutical actively invests in research and development, with a specific focus on creating therapies for intractable diseases. The company has also forged strategic collaborations, including a partnership with Amarin Corporation plc for the advancement and market introduction of ethyl icosapentate products. Furthermore, it collaborates with Gene Techno Science Co., Ltd. to innovate regenerative medicine targeting rare and challenging digestive disorders, such as congenital isolated hypoganglionosis.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Naoyuki Mochida
- Employees
- 1,479
- Website
- www.mochida.co.jp
- Address
- 7, Yotsuya 1-chome, Tokyo, TY, 160-8515, JP
Mochida Pharmaceutical Co., Ltd. (MFY) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 2 |
| Technical Analysis | 3 | 4 | 2 |
| Moving Averages | 12 | 0 | 0 |
